Compare Alcon AG (ALC) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Starbucks Corp — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Starbucks Corp trades at $103.6 (market cap $118.08B). The key difference: Starbucks Corp is far larger — about 3.6× Alcon AG's market cap, and Starbucks Corp pays the higher dividend (2.39%). Which is the better fit depends on your goals.
| ALC | SBUX | |
|---|---|---|
Market Cap | $32.69B | $118.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $106.82 |
52-Week Low | $62.02 | $78.46 |
Enterprise Value | $36.28B | $140.78B |
Dividend Yield | 0.54% | 2.39% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Starbucks (SBUX) trades at $103.61, down 0.62% with a bullish technical signal despite recent price weakness. The company shows mixed fundamentals with declining net income margins (3.89% in 2025) but stable revenue growth. Recent earnings beat expectations in Q1 2026 after two consecutive misses. Analyst consensus remains positive with a $107.67 price target, though technical indicators show neutral oscillators and key resistance at $104.
SBUX faces margin pressure but benefits from strong brand loyalty and store traffic initiatives. Investment opportunity lies in international expansion and operational improvements, while risks include competitive pressures and cost inflation. The stock offers moderate upside potential with balanced analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
